The term identifies recent developments concerning a precancerous plasma cell disorder. This condition, characterized by the presence of abnormal plasma cells in the bone marrow without causing end-organ damage, has been the subject of ongoing research aimed at refining diagnostic criteria and management strategies.
The significance of understanding advancements in this area lies in the potential for early intervention and prevention of progression to active multiple myeloma. Historically, management involved observation alone. However, newer insights are exploring the feasibility and efficacy of early treatments to delay or prevent the onset of symptomatic disease, impacting patient outcomes and quality of life.
